A defining 2026 milestone in the industry is the shift toward Neoadjuvant and Adjuvant usage. In 2026, the market is identifying a trend where Keytruda is used before surgery to shrink tumors (neoadjuvant) or after surgery (adjuvant) in lung and melanoma cases. This 2026 strategy is vital because it moves the drug from being a "last resort" for metastatic patients to a "curative-intent" tool...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek